The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the developmental work this pharma icon has going on. At the very least, the drug ...
GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results